Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 467

1.

Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases.

Dodds TJ, Wilmott JS, Jackett LA, Lo SN, Long GV, Thompson JF, Scolyer RA.

Pathology. 2018 Nov 26. pii: S0031-3025(18)30325-8. doi: 10.1016/j.pathol.2018.09.060. [Epub ahead of print]

PMID:
30497801
2.

ASO Author Reflections: Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas.

Thompson JF, Scolyer RA, Lo SN.

Ann Surg Oncol. 2018 Nov 9. doi: 10.1245/s10434-018-7014-4. [Epub ahead of print] No abstract available.

PMID:
30414034
3.

Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy.

Lim SY, Lee JH, Gide TN, Menzies AM, Guminski A, Carlino MS, Breen EJ, Yang JYH, Ghazanfar S, Kefford RF, Scolyer RA, Long GV, Rizos H.

Clin Cancer Res. 2018 Nov 8. pii: clincanres.2795.2018. doi: 10.1158/1078-0432.CCR-18-2795. [Epub ahead of print]

PMID:
30409824
4.

Epigenetic profiling for the molecular classification of metastatic brain tumors.

Orozco JIJ, Knijnenburg TA, Manughian-Peter AO, Salomon MP, Barkhoudarian G, Jalas JR, Wilmott JS, Hothi P, Wang X, Takasumi Y, Buckland ME, Thompson JF, Long GV, Cobbs CS, Shmulevich I, Kelly DF, Scolyer RA, Hoon DSB, Marzese DM.

Nat Commun. 2018 Nov 6;9(1):4627. doi: 10.1038/s41467-018-06715-y.

5.

Brain metastasis DNA methylomes, a novel resource for the identification of biological and clinical features.

Salomon MP, Orozco JIJ, Wilmott JS, Hothi P, Manughian-Peter AO, Cobbs CS, Scolyer RA, Hoon DSB, Marzese DM.

Sci Data. 2018 Nov 6;5:180245. doi: 10.1038/sdata.2018.245.

6.

Correlation Between Surgical and Histologic Margins in Melanoma Wide Excision Specimens.

Friedman EB, Dodds TJ, Lo S, Ferguson PM, Beck M, Saw RPM, Stretch JR, Lee KK, Nieweg OE, Spillane AJ, Scolyer RA, Thompson JF.

Ann Surg Oncol. 2018 Oct 16. doi: 10.1245/s10434-018-6858-y. [Epub ahead of print]

PMID:
30327975
7.

The steadily growing problem of lentigo maligna and lentigo maligna melanoma in Australia: Population-based data on diagnosis and management.

Guitera P, Collgros H, Madronio CM, Goumas C, Mann GJ, Watts CG, Pereira AR, Armstrong BK, Drummond M, Morton RL, Scolyer RA, Menzies SW, Thompson JF, Cust AE.

Australas J Dermatol. 2018 Oct 9. doi: 10.1111/ajd.12928. [Epub ahead of print]

PMID:
30302753
8.

Sentinel lymph node biopsy remains the most accurate method of obtaining staging and prognostic information for patients with primary cutaneous melanomas.

Friedman EB, Moncrieff MD, Lo S, Scolyer RA, Thompson JF.

Australas J Dermatol. 2018 Oct 7. doi: 10.1111/ajd.12942. [Epub ahead of print] No abstract available.

PMID:
30294907
9.

A Reduction in Inflammatory Macrophages May Contribute to Skin Cancer Chemoprevention by Nicotinamide.

Minocha R, Martin AJ, Chen AC, Scolyer RA, Lyons JG, McKenzie CA, Madore J, Halliday GM, Damian DL.

J Invest Dermatol. 2018 Sep 20. pii: S0022-202X(18)32584-3. doi: 10.1016/j.jid.2018.08.018. [Epub ahead of print] No abstract available.

PMID:
30244097
10.

In reply to Prognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanoma.

Lo SN, Stodell M, Scolyer RA, Thompson JF.

J Am Acad Dermatol. 2018 Sep 15. pii: S0190-9622(18)32504-0. doi: 10.1016/j.jaad.2018.07.068. [Epub ahead of print] No abstract available.

PMID:
30227195
11.

bcGST - an interactive bias-correction method to identify over-represented gene-sets in boutique arrays.

Wang KYX, Menzies AM, Silva IP, Wilmott JS, Yan Y, Wongchenko M, Kefford RF, Scolyer RA, Long GV, Tarr G, Mueller S, Yang JYH.

Bioinformatics. 2018 Sep 12. doi: 10.1093/bioinformatics/bty783. [Epub ahead of print]

PMID:
30215668
12.

Sentinel lymph node biopsy in patients with thin melanomas: Frequency and predictors of metastasis based on analysis of two large international cohorts.

Isaksson K, Nielsen K, Mikiver R, Nieweg OE, Scolyer RA, Thompson JF, Ingvar C.

J Surg Oncol. 2018 Sep;118(4):599-605. doi: 10.1002/jso.25208. Epub 2018 Sep 9.

PMID:
30196533
13.

Advantages of whole-genome sequencing for identification of tumor etiology and clinically actionable genomic aberrations: lessons from the Australian Melanoma Genome Project.

Wilmott JS, Hayward NK, Mann GJ, Scolyer RA.

Melanoma Manag. 2017 Sep;4(3):147-149. doi: 10.2217/mmt-2017-0008. Epub 2017 Jul 26. No abstract available.

14.

Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility.

Wilmott JS, Johansson PA, Newell F, Waddell N, Ferguson P, Quek C, Patch AM, Nones K, Shang P, Pritchard AL, Kazakoff S, Holmes O, Leonard C, Wood S, Xu Q, Saw RPM, Spillane AJ, Stretch JR, Shannon KF, Kefford RF, Menzies AM, Long GV, Thompson JF, Pearson JV, Mann GJ, Hayward NK, Scolyer RA.

Int J Cancer. 2018 Sep 4. doi: 10.1002/ijc.31791. [Epub ahead of print]

PMID:
30178487
15.

Oral malignant gastrointestinal neuroectodermal tumour with junctional component mimicking mucosal melanoma.

Allanson BM, Weber MA, Jackett LA, Chan C, Lau L, Ziegler DS, Warby M, Mayoh C, Cowley MJ, Tucker KM, Long GV, Maher A, Anazodo A, Scolyer RA.

Pathology. 2018 Oct;50(6):648-653. doi: 10.1016/j.pathol.2018.07.002. Epub 2018 Aug 31.

PMID:
30177220
16.

SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling.

Strub T, Ghiraldini FG, Carcamo S, Li M, Wroblewska A, Singh R, Goldberg MS, Hasson D, Wang Z, Gallagher SJ, Hersey P, Ma'ayan A, Long GV, Scolyer RA, Brown B, Zheng B, Bernstein E.

Nat Commun. 2018 Aug 24;9(1):3440. doi: 10.1038/s41467-018-05966-z.

17.

Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis.

Krisp C, Parker R, Pascovici D, Hayward NK, Wilmott JS, Thompson JF, Mann GJ, Long GV, Scolyer RA, Molloy MP.

Br J Cancer. 2018 Sep;119(6):713-723. doi: 10.1038/s41416-018-0227-2. Epub 2018 Aug 17.

PMID:
30116025
18.

Correction to: Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond.

Gershenwald JE, Scolyer RA.

Ann Surg Oncol. 2018 Aug 13. doi: 10.1245/s10434-018-6689-x. [Epub ahead of print]

PMID:
30105437
19.

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.

Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, van de Wiel BA, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, van Akkooi ACJ, van Houdt WJ, Mitchell TC, Menzies AM, Long GV, Wargo JA, Davies MA, Prieto VG, Taube JM, Scolyer RA.

Ann Oncol. 2018 Aug 1;29(8):1861-1868. doi: 10.1093/annonc/mdy226.

PMID:
29945191
20.

Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling.

Griewank KG, Koelsche C, van de Nes JAP, Schrimpf D, Gessi M, Möller I, Sucker A, Scolyer RA, Buckland ME, Murali R, Pietsch T, von Deimling A, Schadendorf D.

Clin Cancer Res. 2018 Sep 15;24(18):4494-4504. doi: 10.1158/1078-0432.CCR-18-0763. Epub 2018 Jun 11.

PMID:
29891723
21.

Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond.

Gershenwald JE, Scolyer RA.

Ann Surg Oncol. 2018 Aug;25(8):2105-2110. doi: 10.1245/s10434-018-6513-7. Epub 2018 May 30. No abstract available. Erratum in: Ann Surg Oncol. 2018 Aug 13;:.

PMID:
29850954
22.

Melanoma protective antitumor immunity activated by catalytic DNA.

Cai H, Cho EA, Li Y, Sockler J, Parish CR, Chong BH, Edwards J, Dodds TJ, Ferguson PM, Wilmott JS, Scolyer RA, Halliday GM, Khachigian LM.

Oncogene. 2018 Sep;37(37):5115-5126. doi: 10.1038/s41388-018-0306-0. Epub 2018 May 29.

PMID:
29844573
23.

FISH analysis of selected soft tissue tumors: Diagnostic experience in a tertiary center.

Vargas AC, Selinger C, Satgunaseelan L, Cooper WA, Gupta R, Stalley P, Brown W, Soper J, Schatz J, Boyle R, Thomas DM, Tattersall MHN, Bhadri V, Maclean F, Bonar SF, Scolyer RA, Karim RZ, McCarthy SW, Mahar A, O'Toole SA.

Asia Pac J Clin Oncol. 2018 May 28. doi: 10.1111/ajco.12980. [Epub ahead of print]

PMID:
29806089
24.

Telomere sequence content can be used to determine ALT activity in tumours.

Lee M, Teber ET, Holmes O, Nones K, Patch AM, Dagg RA, Lau LMS, Lee JH, Napier CE, Arthur JW, Grimmond SM, Hayward NK, Johansson PA, Mann GJ, Scolyer RA, Wilmott JS, Reddel RR, Pearson JV, Waddell N, Pickett HA.

Nucleic Acids Res. 2018 Jun 1;46(10):4903-4918. doi: 10.1093/nar/gky297.

25.

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.

Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer RA, Menzies AM, McArthur GA.

Lancet Oncol. 2018 May;19(5):672-681. doi: 10.1016/S1470-2045(18)30139-6. Epub 2018 Mar 27.

PMID:
29602646
26.

CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment.

Edwards J, Wilmott JS, Madore J, Gide TN, Quek C, Tasker A, Ferguson A, Chen J, Hewavisenti R, Hersey P, Gebhardt T, Weninger W, Britton WJ, Saw RPM, Thompson JF, Menzies AM, Long GV, Scolyer RA, Palendira U.

Clin Cancer Res. 2018 Jul 1;24(13):3036-3045. doi: 10.1158/1078-0432.CCR-17-2257. Epub 2018 Mar 29.

PMID:
29599411
27.

Pigmented Paget's disease of the nipple mistaken for melanoma in situ: a diagnostic pitfall for the unwary.

Solinas A, Mahar A, Cooper WA, Thompson JF, Spillane AJ, Scolyer RA.

Pathology. 2018 Apr;50(3):364-367. doi: 10.1016/j.pathol.2017.09.018. Epub 2018 Mar 1. No abstract available.

PMID:
29490872
28.

Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy.

Star P, Goodwin A, Kapoor R, Conway RM, Long GV, Scolyer RA, Guitera P.

Eur J Cancer. 2018 Mar;92:48-53. doi: 10.1016/j.ejca.2017.12.022. Epub 2018 Feb 3.

PMID:
29413689
29.

Impact of genomics on the surgical management of melanoma.

Ferguson PM, Long GV, Scolyer RA, Thompson JF.

Br J Surg. 2018 Jan;105(2):e31-e47. doi: 10.1002/bjs.10751. Review.

PMID:
29341162
30.

Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas: A Breslow Thickness Cut Point of 0.8 mm Separates Higher-Risk and Lower-Risk Tumors.

Lo SN, Scolyer RA, Thompson JF.

Ann Surg Oncol. 2018 Apr;25(4):894-902. doi: 10.1245/s10434-017-6325-1. Epub 2018 Jan 12.

PMID:
29330716
31.

RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells.

Qutob N, Masuho I, Alon M, Emmanuel R, Cohen I, Di Pizio A, Madore J, Elkahloun A, Ziv T, Levy R, Gartner JJ, Hill VK, Lin JC, Hevroni Y, Greenberg P, Brodezki A, Rosenberg SA, Kosloff M, Hayward NK, Admon A, Niv MY, Scolyer RA, Martemyanov KA, Samuels Y.

Sci Rep. 2018 Jan 12;8(1):653. doi: 10.1038/s41598-017-18851-4.

32.

High response rate to PD-1 blockade in desmoplastic melanomas.

Eroglu Z, Zaretsky JM, Hu-Lieskovan S, Kim DW, Algazi A, Johnson DB, Liniker E, Ben Kong, Munhoz R, Rapisuwon S, Gherardini PF, Chmielowski B, Wang X, Shintaku IP, Wei C, Sosman JA, Joseph RW, Postow MA, Carlino MS, Hwu WJ, Scolyer RA, Messina J, Cochran AJ, Long GV, Ribas A.

Nature. 2018 Jan 18;553(7688):347-350. doi: 10.1038/nature25187. Epub 2018 Jan 10.

33.

Prognostic Significance of Periadnexal Extension in Cutaneous Melanoma and its Implications for Pathologic Reporting and Staging.

Dodds TJ, Lo S, Jackett L, Nieweg O, Thompson JF, Scolyer RA.

Am J Surg Pathol. 2018 Mar;42(3):359-366. doi: 10.1097/PAS.0000000000000999.

PMID:
29240580
34.

A 14-Protein Signature for Rapid Identification of Poor Prognosis Stage III Metastatic Melanoma.

Sykes EK, McDonald CE, Ghazanfar S, Mactier S, Thompson JF, Scolyer RA, Yang JY, Mann GJ, Christopherson RI.

Proteomics Clin Appl. 2018 May;12(3):e1700094. doi: 10.1002/prca.201700094. Epub 2018 Jan 19.

PMID:
29227041
35.

Conditional survival estimates for cancer patients.

Haydu LE, Scolyer RA, Thompson JF.

Oncotarget. 2017 Oct 4;8(49):84639-84640. doi: 10.18632/oncotarget.21497. eCollection 2017 Oct 17. No abstract available.

36.

Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients.

Lim SY, Lee JH, Welsh SJ, Ahn SB, Breen E, Khan A, Carlino MS, Menzies AM, Kefford RF, Scolyer RA, Long GV, Rizos H.

Biomark Res. 2017 Nov 10;5:32. doi: 10.1186/s40364-017-0112-9. eCollection 2017.

37.

Trajectories of premalignancy during the journey from melanocyte to melanoma.

Colebatch AJ, Scolyer RA.

Pathology. 2018 Jan;50(1):16-23. doi: 10.1016/j.pathol.2017.09.002. Epub 2017 Nov 10. Review.

PMID:
29132722
38.

Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma.

Gide TN, Wilmott JS, Scolyer RA, Long GV.

Clin Cancer Res. 2018 Mar 15;24(6):1260-1270. doi: 10.1158/1078-0432.CCR-17-2267. Epub 2017 Nov 10. Review.

PMID:
29127120
39.

The Importance of Population-Based Estimates of Melanocytic Pathology.

Bell KJL, Cust AE, Scolyer RA.

JAMA Dermatol. 2018 Jan 1;154(1):15-17. doi: 10.1001/jamadermatol.2017.4061. No abstract available.

PMID:
29094157
40.

Reply to comment on: Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (< 0.1 mm) Sentinel Lymph Node Metastases.

Holtkamp LHJ, Wang S, Wilmott JS, Madore J, Vilain R, Thompson JF, Nieweg OE, Scolyer RA.

Ann Surg Oncol. 2017 Dec;24(Suppl 3):660. doi: 10.1245/s10434-017-6170-2. Epub 2017 Oct 27. No abstract available.

PMID:
29079922
41.

Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy.

Glodde N, Bald T, van den Boorn-Konijnenberg D, Nakamura K, O'Donnell JS, Szczepanski S, Brandes M, Eickhoff S, Das I, Shridhar N, Hinze D, Rogava M, van der Sluis TC, Ruotsalainen JJ, Gaffal E, Landsberg J, Ludwig KU, Wilhelm C, Riek-Burchardt M, Müller AJ, Gebhardt C, Scolyer RA, Long GV, Janzen V, Teng MWL, Kastenmüller W, Mazzone M, Smyth MJ, Tüting T, Hölzel M.

Immunity. 2017 Oct 17;47(4):789-802.e9. doi: 10.1016/j.immuni.2017.09.012.

42.

Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF; for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform.

CA Cancer J Clin. 2017 Nov;67(6):472-492. doi: 10.3322/caac.21409. Epub 2017 Oct 13.

43.

Skp2-Mediated Stabilization of MTH1 Promotes Survival of Melanoma Cells upon Oxidative Stress.

Wang JY, Liu GZ, Wilmott JS, La T, Feng YC, Yari H, Yan XG, Thorne RF, Scolyer RA, Zhang XD, Jin L.

Cancer Res. 2017 Nov 15;77(22):6226-6239. doi: 10.1158/0008-5472.CAN-17-1965. Epub 2017 Sep 25.

44.

Tumor-associated B-cells induce tumor heterogeneity and therapy resistance.

Somasundaram R, Zhang G, Fukunaga-Kalabis M, Perego M, Krepler C, Xu X, Wagner C, Hristova D, Zhang J, Tian T, Wei Z, Liu Q, Garg K, Griss J, Hards R, Maurer M, Hafner C, Mayerhöfer M, Karanikas G, Jalili A, Bauer-Pohl V, Weihsengruber F, Rappersberger K, Koller J, Lang R, Hudgens C, Chen G, Tetzlaff M, Wu L, Frederick DT, Scolyer RA, Long GV, Damle M, Ellingsworth C, Grinman L, Choi H, Gavin BJ, Dunagin M, Raj A, Scholler N, Gross L, Beqiri M, Bennett K, Watson I, Schaider H, Davies MA, Wargo J, Czerniecki BJ, Schuchter L, Herlyn D, Flaherty K, Herlyn M, Wagner SN.

Nat Commun. 2017 Sep 19;8(1):607. doi: 10.1038/s41467-017-00452-4.

45.

Punch 'scoring': a technique that facilitates melanoma diagnosis of clinically suspicious pigmented lesions.

Grogan J, Cooper CL, Dodds TJ, Guitera P, Menzies SW, Scolyer RA.

Histopathology. 2018 Jan;72(2):294-304. doi: 10.1111/his.13342. Epub 2017 Oct 17.

PMID:
28796900
46.

Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients.

Kakavand H, Jackett LA, Menzies AM, Gide TN, Carlino MS, Saw RPM, Thompson JF, Wilmott JS, Long GV, Scolyer RA.

Mod Pathol. 2017 Dec;30(12):1666-1676. doi: 10.1038/modpathol.2017.89. Epub 2017 Aug 4.

47.

Neurotropic melanoma: an analysis of the clinicopathological features, management strategies and survival outcomes for 671 patients treated at a tertiary referral center.

Varey AHR, Goumas C, Hong AM, Mann GJ, Fogarty GB, Stretch JR, Saw RPM, Spillane AJ, Shannon KF, Lee KJ, Quinn MJ, Thompson JF, Scolyer RA.

Mod Pathol. 2017 Nov;30(11):1538-1550. doi: 10.1038/modpathol.2017.76. Epub 2017 Jul 21.

48.

PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.

Kakavand H, Rawson RV, Pupo GM, Yang JYH, Menzies AM, Carlino MS, Kefford RF, Howle JR, Saw RPM, Thompson JF, Wilmott JS, Long GV, Scolyer RA, Rizos H.

Clin Cancer Res. 2017 Oct 15;23(20):6054-6061. doi: 10.1158/1078-0432.CCR-16-1688. Epub 2017 Jul 19.

49.

Germline BAP1 mutations also predispose to cutaneous squamous cell carcinoma.

Rawson RV, Watson GF, Maher AM, McCarthy SW, Thompson JF, Scolyer RA.

Pathology. 2017 Aug;49(5):539-542. doi: 10.1016/j.pathol.2017.03.005. Epub 2017 Jul 8. No abstract available.

PMID:
28693747
50.

Recurrent bowel obstruction: unusual presentation of pembrolizumab-induced pancreatitis in annular pancreas.

Rawson RV, Robbins E, Kapoor R, Scolyer RA, Long GV.

Eur J Cancer. 2017 Sep;82:167-170. doi: 10.1016/j.ejca.2017.05.042. Epub 2017 Jul 6. No abstract available.

PMID:
28689094

Supplemental Content

Loading ...
Support Center